PRESS RELEASE
ERYTECH announces that the Commercial Court has dismissed Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma
Lyon (France), June 14, 2023 – 8:00 p.m. – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells, today announces that the court de Commerce de Lyon rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma.
Erytech welcomes the interim order issued today by the President of the Commercial Court of Lyon. The latter rejected the attempt by Akkadian Partners to obtain the postponement of the vote on the merger. Consequently, Erytech shareholders will be able to validly vote on the merger on June 23, 2023.
An expert has been appointed to examine the merger parity and will have to submit his report to the parties within 4 months. This expertise must be carried out at the expense of Akkadian Partners, which has also been ordered to compensate Erytech for the costs that the company has incurred in the context of the procedure.
About ERYTECH:
www.erytech.com
ERYTECH is a biopharmaceutical company that develops innovative treatments based on red blood cells to fight against cancers and orphan diseases.
On February 15, 2023, ERYTECH announced its planned strategic merger with PHERECYDES to create a global player in phage therapy. More details are available in the press release.
ERYTECH is listed on the Nasdaq Capital Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
For more information, please visit www.erytech.com
CONTACTS
ERYTECH Eric Soyer Chief Financial Officer and Director of Operations |
NewCap Mathilde Bohin/Louis-Victor Delouvrier Investor Relations Nicolas Merigeau Media Relations |
+33 (0)4 78 74 44 38 | +33 (0)1 44 71 94 94 |
Attachment
CP_ERYTECH_14062023_FR_VF